The growth of endometrial cells in ectopic locations (endometriosis) is dependent on the establishment of an adequate blood supply. Neovascularization (angiogenesis) is therefore a vital step toward the progression of this disease. We first revealed the presence of a potent mitogenic activity for human endothelial cells in the culture medium of immortalized human endometriotic cells. The activity, measured by the level of [
with human macrophage migration inhibitory factor (MIF). The protein was positively identified as MIF by Western blot analysis using a specific anti-MIF antibody. Anti-MIF antibody inhibited the bioactivity found in the evaluated fraction and the conditioned medium of primary endometriotic cell cultures, and commercial recombinant human MIF displayed a high mitogenic activity for endothelial cells. Our findings reveal that MIF is released by endometriotic cells and acts as a potent mitogenic factor for human endothelial cells in vitro. This may have a considerable interest, in view of the crucial role of angiogenesis in ectopic endometrial cell growth and activity and in numerous tissues undergoing dynamic physiological changes, such as human endometrium. E NDOMETRIOSIS IS ONE of the most common gynecological diseases, and it affects about 10% of women of reproductive age (1) . The cause(s) of endometriosis remains obscure, but it is thought to arise from the implantation and growth of exfoliated menstrual endometrium outside the uterus, mainly in the peritoneal cavity (2) . According to this widely accepted hypothesis, the survival and growth of the ectopically implanted endometrial tissue requires a de novo blood supply and dynamic vascular remodeling, both essential to the development of endometriosis. Angiogenesis, the process by which new blood vessels develop, is currently the focus of mounting interest (3) . Angiogenesis is critical to normal reproductive function; tightly regulated angiogenesis occurs during follicular maturation, endometrial growth, and menstruation and during placentation and embryonic development (4, 5) . Angiogenesis is also implicated in neoplastic (6, 7) and nonneoplastic diseases such as arthritis (8) and arteriosclerosis (9) .
In the course of the normal menstrual cycle, the endometrium undergoes profuse increases in the length, branching, and coiling of spiral arteries (10) . However, more aggressive angiogenesis may occur in the peritoneal cavity of women with endometriosis (11) ; the establishment of the explant not only depends on the maintenance of the blood vessels within the ectopic endometrium but also on the growth of new blood vessels, through the peritoneum, to sustain the foreign endometrium (12) . Active endometriotic explants have pronounced vascularization both within and around the tissue (13) .
Several angiogenic factors have been identified, including acidic and basic fibroblast growth factors, platelet-derived endothelial cell growth factor, and vascular endothelial cell growth factor (VEGF) (14 -16) . The identification of the mediators of angiogenesis involved in endometriosis and their origins will be instrumental to elucidating the pathogenesis of the disease. In the peritoneal fluid, which bathes the peritoneal and ovarian surface where most endometriotic lesions occur, an elevated angiogenic activity was found in women with endometriosis, compared with normal women (17) . Higher peritoneal concentrations of VEGF were also demonstrated in women with moderate to severe endometriosis than in women without the disease (18, 19) . Peritoneal and resident macrophages found in endometriotic lesions seemed to be the major sources of VEGF secretion (19) . However, we also believe that endometrial cells capable of aberrant implantation and growth in ectopic locations produce angiogenic factors that ensure their survival and development. In the present study, we show that immortalized endometriotic epithelial cells produce factors that promote human endothelial cell proliferation, and reveal a similar activity in the culture medium of primary endometriotic cell cultures. Of the mitogenic fractions isolated from the conditioned medium of the endometriotic cell line, one contained macrophage migration inhibitory factor (MIF), which displayed a potent mitogenic activity for endothelial cells and seemed to be a major mediator of the mitogenic activity released by immortalized and primary endometriotic cells.
Materials and Methods

Source and handling of tissue
Endometriotic biopsies were collected, at laparoscopy, from three women who had given an informed consent for a research protocol approved by the Saint-François d'Assise Hospital Ethics Committee on Human Research. These women were between 32 and 39 yr old, consulted for infertility and/or pelvic pain, had no endometrial hyperplasia or neoplasia, and had not received any antiinflammatory or hormonal medication during a period of at least 3 months before surgery. One woman had revised American Fertility Society stage I endometriosis, and two had stage II. Endometriotic biopsies were from brownish lesions and peritoneal red vesicles. As soon as they were collected, the biopsies were placed, at 4 C, in sterile HBSS containing 100 U/mL penicillin, 100 g/mL streptomycin, and 0.25 g/mL amphotericin and were transported to the laboratory. The biopsy specimens were examined histologically, and the diagnosis of endometriosis was confirmed, in all cases, by the identification of both glandular and stromal endometrial elements.
Culture of primary and immortalized endometriotic cells
Endometriotic tissue was immediately minced into small pieces and dissociated with collagenase, as previously described (see Ref. 35) . Cells were pelleted by centrifugation (200 ϫ g/10 min); resuspended in DMEM-F12 containing 10 g/mL insulin, 5 g/mL transferrin, 10% FBS, 100 U/mL penicillin, 100 g/mL streptomycin, and 2.5 g/mL Amphotericin B (Life Technologies, Inc., Burlington, Ontario, Canada); and plated in 100-mm-diameter culture dishes; then grown, at 37 C, in 5% carbon dioxide. Both tadpole-shaped epithelial and fibroblast-like stromal cells were present in culture, as identified morphologically by light microscopy and immunocytochemically with specific monoclonal antibodies to cytokeratins and vimentin, as previously described (see Ref. 35) . No leukocytes were detected in the endometriotic cells detached from culture dishes and assessed by flow cytometry (data not shown).
Endometriotic cell line Clo03 (20) was cultured in 100-mm-diameter culture dishes and maintained at 37 C, 5% CO 2 in the same culture medium described above.
Preparation of conditioned media from endometriotic cell cultures
At confluence, cells were rinsed four times with HEPES buffered saline to eliminate FBS, then incubated for 24 h with M199 medium (Life Technologies, Inc.) (6 mL/Petri dish). The conditioned medium from primary endometriotic cell cultures (PCM) or from endometriotic cell line culture (LCM) was collected afterwards on ice, centrifuged to eliminate cell debris, concentrated and diafiltrated using Amicon's YM1 membranes (Millipore Corp., Nepean, ON, Canada), aliquoted, and stored at Ϫ70 C until biological assay or further purification. The protein content of the samples was measured by Micro BCA Protein Assay Reagent Kit (Pierce Chemical Co., Rockford, IL) and analyzed by SDS-PAGE in an electrophoresis system (Mini-Protean II, Bio-Rad Laboratories, Inc. Ltd, Mississauga, ON, Canada), according to Laemmli et al. (21) . Bands were visualized by silver staining.
Purification of angiogenic factors from LCM
The chromatographic system consisted of two 2150 pumps, a gradient controller, and a 2221 integrator (Pharmacia Biotech, Baie d'Urfé, PQ, Canada). A Mono Q HR 5/5 anion exchange column (Pharmacia) was used for high-resolution separation of proteins. Two mg of LCM in 500 L of 20-mm phosphate buffer (pH 7.0) were loaded using a 2154 high-performance liquid chromatography (HPLC) injection valve with 500-L loop at a flow rate of 1 mL/min. Column eluates were monitored by ultraviolet absorbance, at 216 nm, using a 2158 Uvicord sd detector. Eight fractions, eluted by a sodium chloride (NaCl) step-wise gradient (0, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 1 m NaCl), were collected separately, concentrated with Amicon's YM1 membranes (Millipore Corp.), aliquoted, and saved at Ϫ70 C until being analyzed by SDS-PAGE and tested for mitogenic activity.
One of the fractions exerting a significant mitogenic action on human endothelial cells (F1, obtained with 0 m NaCl) was selected for further analyses, because it exhibited the lowest number of bands by electrophoresis. F1 was fractionated, using a Microcon-10 microconcentrator (Millipore Corp.), and both the lower part (F1a) and the upper part (F1b) were collected, aliquoted, and saved at Ϫ70 C until assay.
Analysis of cell proliferation
Endothelial cells from human coronary arteries (HCAEC, Cell Systems, Kirkland, WA) were cultured according to the supplier's specifications. Briefly, cells were seeded in 24-well culture plates (4 ϫ 10 4 cells/well) precoated with attachment factor and feeded with CS-C complete serum-free medium (Cell Systems). The medium was refreshed every 24 h; at 60 -70% confluence, cells were rinsed twice with HEPES buffered saline/Ca/Mg and incubated with CS-C mitogen-free medium (Cell Systems) for 24 h at 37 C, 5% CO 2 . Cells were then exposed, in fresh CS-C mitogen-free medium, to different concentrations of the evaluated substances, or to 10 g/mL of endothelial cell growth supplement (ECGS) (Cell Systems), which was included as positive control in each experiment. For neutralization experiments, bioactive fractions were incubated, for 1 h at 37 C, with different concentrations of polyclonal goat anti-MIF antibody (10 -1000 ng/mL) (R and D Systems, Minneapolis, MN) or with equivalent concentrations of normal goat IgGs (R and D Systems) before being added to endothelial cell cultures. Twelve hours later, 2.5 Ci [
3 H]-thymidine (SA, 20 Ci/mmol; NEN Life Science Products, Boston, MA) were added to each well, and incubation was continued for 12 h more. The media were then discarded; and cells were washed twice with ice-cold PBS, fixed for 20 min in cold methanol, treated for 30 min at 4 C with 10% trichloroacetic acid, rinsed with cold ethanol, air dried, and dissolved in 0.5 mL of 0.6-n sodium hydroxide. After neutralization with 0.5 mL of 0.6-n chlorhydric acid (HCl), the radioactivity was measured by liquid scintillation spectrometry. Mitogenic activity was expressed as [ 3 H]-thymidine incorporation percentage of control (medium without mitogens).
Amino acid sequence analysis
After purification by HPLC and a Microcon-10 microconcentrator, 20 g of the bioactive fraction (F1a) were separated by SDS-PAGE as follows: Aliquots were heated to 37 C for 15 min before loading, and 100 mm sodium triglycolate (ICN Biomedicals, Inc., Aurora, OH) was added to the upper reservoir to prevent N-terminal blocking during electrophoresis (22) . Proteins were visualized by Coomassie blue R-250 (0.1% solution in 50% methanol), individual bands were cut, and in-gel enzymatic digestion was carried out, for 24 h at 37 C, according to Williams et al. (23) using lysylendopeptidase (Wako Pure Chemical Industries Ltd., Richmond, VA). The resulting peptides were fractionated on a 1090 HPLC system (Hewlett-Packard Co., Palo Alto, CA) using a 1 mm ϫ 25 cm C-18 reverse-phase column (5 m, 300 pore size) (Vydac, Hesperia, CA) equilibrated with 98% buffer A [trifluoroacetic acid 0.1%] and 2% buffer B (80% acetonitrile, 0.08% trifluoroacetic acid). Peptides were eluted, at 50 L/min, with a linear gradient of buffer B and were detected by ultraviolet absorbance at 216 mm. Selected peptides were then subjected to N-terminal sequencing by automatic Edman degradation performed on a model 473A pulsed liquid protein sequencer (PE Applied Biosystems, Foster City, CA). Analysis was performed by the Eastern Quebec Proteomics Core Facility (CHUQ, Sainte-Foy, PQ, Canada).
Western blot analysis
Proteins in the F1a fraction (1 g) and PCM (1 and 10 g) were separated under reducing conditions in 15% SDS-PAGE, as mentioned earlier, and transferred, during 2 h at 4 C and 250 mA, onto a 0.22-m nitrocellulose membrane using electrophoretic transfer cell (Trans-Blot, Bio-Rad Laboratories, Inc.). The nitrocellulose membrane was then incubated, for 4 h at room temperature, in a solution containing 5% skimmed milk in 0.1 m Tris buffer, 0.9% NaCl, 0.05% Tween 20, pH 7.2 (TBST blocking solution) and 3% normal rabbit serum. The membrane was then cut into strips and incubated with an affinity-purified polyclonal goat anti-MIF antibody (2 g/mL in TBST blocking solution) (R and D Systems) or with normal goat immunoglobulins (IgGs) (R and D Systems) at equivalent concentration, overnight at 4 C. Thereafter, the strips were incubated, for 1 h at room temperature, with peroxidaselabeled rabbit antigoat IgG antibodies (Fc specific) diluted 1:10,000 (Sigma, St. Louis, MO), washed, and incubated with chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech, Oakville, Ontario, Canada) for 1 min, air dried, wrapped in a plastic bag, and exposed to X-OMAT AR film (Eastman Kodak Co., Rochester, NY) for 15 sec.
Statistical analysis
Values represent the mean of triplicate measurements. Data were analyzed using one-way ANOVA. A post hoc Tukey's test was used for multiple comparisons. Differences were considered statistically significant for P values Ͻ 0.05.
Results
Detection and purification of mitogenic activity
The conditioned medium derived from Clo03 cell line, concentrated by Amicon's YM1 membranes, stimulated the incorporation of [
3 H]-thymidine into the DNA of HCAEC in a dose-dependent manner. Figure 1 illustrates results from three independent experiments showing that the level of The conditioned medium was further fractionated by HPLC using ion-exchange chromatography and a step-wise 0 -1-m NaCl gradient. Eight fractions eluted with 0, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 1 m NaCl were collected separately and evaluated for the presence of endothelial cell growthpromoting activity. The activity was mainly recovered in fractions 1, 2, and 8, which were eluted with 0, 0.3, and 1 m NaCl, respectively (data not shown).
In the present work, only F1 was considered for further investigations because electrophoretic analysis of this fraction showed it contained fewer bands than both the initial material (LCM) (Fig. 2) and the two other bioactive fractions F2 and F8 (data not shown).
Because our attempts to isolate the mitogenic factor(s) from F1 using chromatographic procedures were unsuccessful, we decided to separate low-and high-molecular-weight molecules of the fraction by ultrafiltration using Amicon's ultrafiltration membranes. Using a Microcon-10 microconcentrator, three proteins [with estimated molecular masses of 15.8, 12.6, and 6.5 kDa (Fig. 2) ] were isolated from F1 and recovered in the pass-through fraction (F1a). The biological assay of F1a revealed potent mitogenic activity toward endothelial cells. Such activity, expressed as [
3 H]-thymidine incorporation percentage of control, was significant at as low as 1 pg/mL (133.7 Ϯ 5.8%; P Ͻ 0.05), increased as a function of F1a concentration in culture [reaching a maximal level at 0.1 ng/mL (177.3 Ϯ 15.0%; P Ͻ 0.01)[, and gradually decreased afterwards at higher concentrations: 1 ng/mL (163.5 Ϯ 10.7; P Ͻ 0.05) and 10 ng/mL (153.8 Ϯ 9.0%; P Ͻ 0.05).
Identification and evaluation of MIF mitogenic activity
The in-gel lysylendopeptidase digestion of the 12.6-kDa band of F1a, followed by HPLC purification and N-terminal sequencing of 11 aminoacids from an internal 1.18-kDa peptide, revealed 100% identity with the human MIF (hMIF). As shown in Fig. 3A , the 11-aminoacids sequence perfectly matched that between amino acids 68 and 78 of hMIF, whose reported molecular mass (12.476 kDa) is very close to that of the 12.6-kDa protein. Moreover, the 12.6-kDa band was specifically recognized by an affinity-purified polyclonal goat anti-hMIF antibody, as shown by Western blot analysis of F1a fraction and PCM (Fig. 3B) . This provides strong evi- 
FIG. 2. SDS-PAGE analysis of LCM (lane B), F1 (lane D), and F1a
(lane E) obtained from F1 by ultrafiltration using a Microcon-10 microconcentrator. LCM (2.2 g) was loaded in 10% acrylamide gel, whereas F1 (1 g) and F1a (1.5 g) were loaded in 15% acrylamide gel, and proteins were revealed by silver staining. Lanes A and B represent broad-range and low-range molecular mass markers, respectively.
dence for the identification of this protein as human MIF and demonstrates its secretion by primary ectopic endometrial cell cultures.
To determine whether MIF had any inherent mitogenic activity toward endothelial cells, the bioactive fraction F1a was incubated with different concentrations of the anti-MIF antibody (1-50 g/mL) or with equivalent concentrations of nonspecific goat IgGs before being added to endothelial cell cultures. As shown in Fig. 4 , the endothelial cell growthpromoting activity of F1a was significantly inhibited by the antibody (P Ͻ 0.01), whereas nonspecific goat IgGs had no significant effect. Recombinant MIF was then assessed for its ability to promote endothelial cell proliferation, and (as illustrated in Fig. 5 ) the protein displayed dose-dependent mitogenic action on HCAEC. This effect was statistically significant at 0.1 pg/mL (164 Ϯ 15% of control, P Ͻ 0.05) and reached its highest level at 100 pg/mL (266 Ϯ 23% of control, P Ͻ 0.01).
Detection of MIF-related mitogenic activity in primary endometriotic cell culture medium
We finally assessed whether primary endometriotic cell cultures release any mitogenic activity for endothelial cells and found that PCM increased 3 H-thymidine incorporation in HCAEC in a dose-dependent manner. The activity was significantly reduced (34 Ϯ 5%, P Ͻ 0.05) after preincubation of PCM with anti-MIF antibody (Fig. 6) .
Discussion
In the present study, we have shown that immortalized human endometriotic cells liberate a potent mitogenic activity for human endothelial cells. Partial purification of the mitogenic factor(s) by anion-exchange chromatography led to the isolation of 3 main bioactive fractions. Further separation by ultrafiltration of one of these fractions resulted in the isolation of 3 proteins of low apparent molecular mass (15.8, 12.6, and 6.5 kDa), which, together, possessed potent endothelial cell growth promoting activity. N-terminal sequencing of an internal peptide obtained from one of these proteins proved it to be 100% homologous to 11 consecutive amino acids of human MIF; and Western blot analysis, using a specific antibody, confirmed the presence of MIF in the fraction.
Antibodies specific to MIF significantly reduced the mitogenic activity displayed by the F1a fraction and that detected in the culture medium of primary endometriotic cells. Recombinant hMIF (over 97% pure, according to the manufacturer) was intrinsically able to promote endothelial cell proliferation (this in a dose-dependent fashion and detectable at as low as 0.1 pg/mL). These findings reveal that MIF is released by endometriotic cells and acts as a potent mediator of the mitogenic activity for human endothelial cells in vitro. This may have a considerable interest, in view of the key role of angiogenesis in the ectopic growth of endometrial cells and the activity of the implants. Interestingly, the present findings coincide with the recent publication of data showing an important role for MIF in tumor growth-associated angiogenesis in vivo, and in vitro in autocrine regulation of microvascular endothelial cell proliferation (24) . This is in keeping with our data, and it further supports the novel role of MIF.
MIF was one of the first reported cytokines. It was originally described as a lymphokine that retained macrophages and inhibited their migration from inflammatory loci (25) (26) (27) , and extensive study of its biological functions has been made possible by the recent cloning of mouse and human MIF genes (28) . Nonetheless, the precise pathophysiological role of MIF remains undefined, and its receptor has yet to be identified. Recently, MIF was reported as an anterior pituitary-derived hormone that can override the glucocorticoidmediated suppression of inflammatory and immune responses (29) . MIF has also been shown to be expressed abundantly by macrophages (30) and to potentiate the proinflammatory actions of these cells (28 -30) . High levels of MIF expression were found in a variety of inflammatory conditions such as atopic dermatitis in the epidermal layer of inflammatory skin lesions (31) , immunologically induced glomerulonephritis (32) (33) (34) , and rat adjuvant arthritis (35) . Available data also indicate that MIF is associated not only with the immune response but also with cell proliferation and differentiation during wound repair (31) and tumor growth (36) . MIF synthesis is up-regulated in human metastatic colon cancer (31) and in metastatic human prostatic adenocarcinoma (37) , and the interaction between tumor cells and macrophages in the latter disease has been shown to stimulate angiogenesis and tissue proliferation (38) . Moreover, MIF was detected in human vascular endothelial cells (31) and was found to be abundantly expressed in human corneal endothelial and epithelial cells (39 -41) after tissue damage, suggesting a possible role in tissue repair and cell growth. These data, along with our results showing MIF as a major growth promoting factor for endothelial cells produced by endometriotic cells, support the hypothesis that MIF is a key autocrine and paracrine mediator involved in neovascularization and tissue remodeling processes.
Endometriosis, defined as the ectopic growth of endometrial tissue, is frequently associated with an immunoinflammatory process observed both eutopically in the endometrium (42) (43) (44) (45) and ectopically in the peritoneal cavity, where the disease frequently develops (46, 47) . Elevated numbers of macrophages was detected in the uterine endometrium (44), within endometriotic lesions (48, 49) , and in the peritoneal cavity of patients suffering from endometriosis (50 -52) . Furthermore, activated peritoneal macrophages were found to be a major source of VEGF, a factor also expressed by tissue macrophages present in endometriotic lesions (19) . Therefore, the finding that MIF can be secreted by endometriotic cells strongly suggests that it may contribute to the angiogenic process via at least two different ways: directly, by stimulating endothelial cell proliferation; and indirectly, by accumulating macrophages. These cells, in addition to their FIG. 4 . Mitogenic activity of 10 g/mL ECGS (PC) and of 100 pg/mL F1a, which was incubated or not with different concentrations of an affinity-purified polyclonal goat anti-MIF antibody (1-50 g/mL) or with equivalent concentrations of nonspecific goat IgGs, for 1 h at room temperature, before being added to endothelial cell cultures. The mitogenic activity was determined as described under Fig. 1 . Values are means Ϯ SEM of triplicate determinations. **, Significant inhibition of F1a mitogenic activity (P Ͻ 0.01).
FIG. 5. Mitogenic activity of 10 g/mL ECGS (PC) and different concentrations of MIF (10 Ϫ4 -10 ng/mL). The mitogenic activity was determined as described under Fig. 1 . Values are means Ϯ SEM of triplicate determinations in three independent experiments. * and **, Significantly different from control (P Ͻ 0.05 and P Ͻ 0.01, respectively).
FIG. 6. Mitogenic activity of primary endometriotic cell culture conditioned medium (PCM). Conditioned media of cultures issued from three different biopsies were processed separately, and each medium was evaluated twice in duplicate. A, HCAEC were incubated with different concentrations of PCM, or with 10 g/mL ECGS (PC), and the mitogenic activity was determined as described under Fig. 1 . Results are expressed as means Ϯ SEM. * and **, Significantly different from control (P Ͻ 0.05 and P Ͻ 0.01, respectively). B, The mitogenic activity of 100 ng/mL PCM was evaluated with and without prior incubation with polyclonal goat anti-MIF (1 g/mL) or normal goat IgGs (1 g/mL). Values are means Ϯ SEM. *, Significantly different from PCM alone (ဧ) (P Ͻ 0.05).
ability to produce VEGF and probably other angiogenic factors, represent a major source of MIF itself, as previously reported (30) . Further studies are required, however, to evaluate the angiogenic activity of MIF in vivo and its expression in different types of endometriotic lesions. In fact, biochemically active endometriosis lesions (53) , such as red vesicles and hemorrhagic lesions, are characterized by increased vascularization both around and within the endometriotic tissue, suggesting active neovascularization or angiogenic processes; whereas pigmented hypovascularized lesions are less active, and white lesions are considered as scars (11, 13) .
Other fractions displaying potent mitogenic activity toward endothelial cells were also isolated in the experiments presented in this paper. Further investigations will be required to identify the factor(s) responsible for this activity and to determine the nature of the proteins that were copurified with MIF in the bioactive fraction F1a and their contribution the mitogenic activity observed.
In conclusion, this investigation revealed that MIF is a novel and a potent growth-promoting factor for human endothelial cells. This could be of considerable interest for the understanding of numerous angiogenesis-associated pathologies or inflammatory conditions, including endometriosis and neovascularization processes occurring in tissues such as human endometrium undergoing dynamic changes.
